NCT00591214View on ClinicalTrials.gov

Safety and PK Study of MP-424 to Treat Chronic Hepatitis C

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Chronic Hepatitis C
Interventions
DRUG

MP-424 (Telaprevir)

Three tablets of MP-424 250mg tablet at a time, every 8 hours, 12 weeks administration (dose in a day: 2250 mg)

Trial Locations (1)

Unknown

Toranomon Hospital, Kawasaki

Sponsors
All Listed Sponsors
collaborator

Vertex Pharmaceuticals Incorporated

INDUSTRY

lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY